Identification of Potential Vaccine Candidates Against SARS-CoV-2 to Fight COVID-19: Reverse Vaccinology Approach

E. Gupta, R. Mishra, Ravi Ranjan Kumar Niraj
{"title":"Identification of Potential Vaccine Candidates Against SARS-CoV-2 to Fight COVID-19: Reverse Vaccinology Approach","authors":"E. Gupta, R. Mishra, Ravi Ranjan Kumar Niraj","doi":"10.2196/32401","DOIUrl":null,"url":null,"abstract":"Background The recent emergence of COVID-19 has caused an immense global public health crisis. The etiological agent of COVID-19 is the novel coronavirus SARS-CoV-2. More research in the field of developing effective vaccines against this emergent viral disease is indeed a need of the hour. Objective The aim of this study was to identify effective vaccine candidates that can offer a new milestone in the battle against COVID-19. Methods We used a reverse vaccinology approach to explore the SARS-CoV-2 genome among strains prominent in India. Epitopes were predicted and then molecular docking and simulation were used to verify the molecular interaction of the candidate antigenic peptide with corresponding amino acid residues of the host protein. Results A promising antigenic peptide, GVYFASTEK, from the surface glycoprotein of SARS-CoV-2 (protein accession number QIA98583.1) was predicted to interact with the human major histocompatibility complex (MHC) class I human leukocyte antigen (HLA)-A*11-01 allele, showing up to 90% conservancy and a high antigenicity value. After vigorous analysis, this peptide was predicted to be a suitable epitope capable of inducing a strong cell-mediated immune response against SARS-CoV-2. Conclusions These results could facilitate selecting SARS-CoV-2 epitopes for vaccine production pipelines in the immediate future. This novel research will certainly pave the way for a fast, reliable, and effective platform to provide a timely countermeasure against this dangerous virus responsible for the COVID-19 pandemic.","PeriodicalId":73552,"journal":{"name":"JMIR bioinformatics and biotechnology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JMIR bioinformatics and biotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2196/32401","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 6

Abstract

Background The recent emergence of COVID-19 has caused an immense global public health crisis. The etiological agent of COVID-19 is the novel coronavirus SARS-CoV-2. More research in the field of developing effective vaccines against this emergent viral disease is indeed a need of the hour. Objective The aim of this study was to identify effective vaccine candidates that can offer a new milestone in the battle against COVID-19. Methods We used a reverse vaccinology approach to explore the SARS-CoV-2 genome among strains prominent in India. Epitopes were predicted and then molecular docking and simulation were used to verify the molecular interaction of the candidate antigenic peptide with corresponding amino acid residues of the host protein. Results A promising antigenic peptide, GVYFASTEK, from the surface glycoprotein of SARS-CoV-2 (protein accession number QIA98583.1) was predicted to interact with the human major histocompatibility complex (MHC) class I human leukocyte antigen (HLA)-A*11-01 allele, showing up to 90% conservancy and a high antigenicity value. After vigorous analysis, this peptide was predicted to be a suitable epitope capable of inducing a strong cell-mediated immune response against SARS-CoV-2. Conclusions These results could facilitate selecting SARS-CoV-2 epitopes for vaccine production pipelines in the immediate future. This novel research will certainly pave the way for a fast, reliable, and effective platform to provide a timely countermeasure against this dangerous virus responsible for the COVID-19 pandemic.
识别对抗新冠肺炎的潜在SARS-CoV-2候选疫苗:反向疫苗学方法
近期新冠肺炎疫情的出现,引发了一场巨大的全球公共卫生危机。COVID-19的病原是新型冠状病毒SARS-CoV-2。在开发针对这一突发病毒性疾病的有效疫苗方面进行更多的研究确实是当务之急。目的寻找有效的候选疫苗,为抗击COVID-19提供新的里程碑。方法采用反向疫苗学方法对印度突出菌株的SARS-CoV-2基因组进行研究。预测抗原表位,然后通过分子对接和模拟验证候选抗原肽与宿主蛋白相应氨基酸残基的分子相互作用。结果从SARS-CoV-2表面糖蛋白中分离出一种极具潜力的抗原肽gvyfastk(蛋白加入号QIA98583.1),可与人主要组织相容性复合体(MHC) I类人白细胞抗原(HLA)-A*11-01等位基因相互作用,保护率高达90%,具有较高的抗原性。经过严格的分析,预测该肽是一个合适的表位,能够诱导针对SARS-CoV-2的强细胞介导免疫应答。结论这些结果可为今后疫苗生产管道中SARS-CoV-2抗原表位的选择提供参考。这项新研究必将为建立一个快速、可靠、有效的平台铺平道路,为应对这种导致COVID-19大流行的危险病毒提供及时的对策。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.90
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信